Sepoy-logo
No Result
View All Result
Wednesday, March 29, 2023
  • Home
  • News
  • Business
  • Health
  • Tech
  • Lifestyle
  • Economy
  • Crypto
  • Travel
  • Home
  • News
  • Business
  • Health
  • Tech
  • Lifestyle
  • Economy
  • Crypto
  • Travel
No Result
View All Result
SEPOY.NET
No Result
View All Result
Home Health

The safety and immunogenicity of a fourth dose of NVX-CoV2373

Nicholas by Nicholas
November 23, 2022
in Health
0
The safety and immunogenicity of a fourth dose of NVX-CoV2373

In a recent study posted to the medRxiv* preprint server, researchers assessed the immunogenicity and safety of a fourth homologous boost dose of a recombinant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein vaccine called NVX-CoV2373.

Study: Immunogenicity and safety of a 4th homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a phase 2, randomized, placebo-controlled trial. Image Credit: Ekaterina Govorina/Shutterstock
Study: Immunogenicity and safety of a 4th homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a phase 2, randomized, placebo-controlled trial. Image Credit: Ekaterina Govorina/Shutterstock

Background

The emergence and rapid spread of SARS-CoV-2 variants, particularly the Omicron sublineages, which include mutations that boost viral transmissibility and increase the viruses’ capacity to resist vaccine protection, might drastically diminish the efficacy of authorized vaccines. The effectiveness of SARS-CoV-2 ancestral strain-based vaccinations against Omicron sublineages is highly dependent on the vaccine’s capacity to produce broadly cross-reactive antibodies.

About the study

In the present study, researchers assessed the immunogenicity and safety of NVX-CoV2373 after a fourth dose.

A subset of healthy adult subjects in an ongoing phase 2 placebo-controlled, randomized investigation of NVX-CoV2373 received a two-dose primary vaccination series. The third and fourth vaccine doses of NVX-CoV2373 were subsequently administered at six-month intervals. The booster immunizations were delivered intramuscularly at a similar dose level as the original vaccination series. This analysis only includes subjects who got four NVX-CoV2373 doses.

Participants used an electronic journal to record systemic and local reactogenicity at the time of vaccination and six days afterward. Unsolicited adverse events were recorded for the first 28 days following vaccination. Serious adverse events (SAEs), vaccine-attributable medically attended adverse events (MAAEs), and adverse events of special interest (AESIs) were recorded till the end of the research. Blood samples were collected for immunogenicity analysis on days zero, 35, 189, 217, and 371 before and after each immunization.

The immune response was evaluated by the following means: (1)  After each dosage of NVX-CoV2373 by means of serum neutralizing antibodies utilizing validated pseudovirus neutralization assays corresponding to ancestral, BA.1, and BA.4/BA.5 variants, (2) by means of an anti-rS IgG assay, and (3) by means of a suitable SARS-CoV-2 human angiotensin-converting enzyme 2 (ACE2) receptor binding inhibition assay. The software was fed serum-neutralizing titers recorded after two, three, and four doses to generate a SARS-CoV-2 antigenic map.

Results

Of the 1,610 individuals screened between 24 August 2020 and 25 September 2020, a total of 1,288 subjects were randomized, while 1,283 were vaccinated with a minimum of one dose of the study vaccine. After six months, 207 of the 258 participants initially assigned to receive two doses of NVX-CoV2373 were re-randomized to be administered a third NVX-CoV2373 dose or a placebo. Approximately 45 patients vaccinated with the third dosage of NVX-CoV2373 were administered the fourth dose six months afterward.

Solicited systemic and local reactogenicity events were reported after each dose of NVX-CoV2373 was administered. However, these events leveled out or declined post-fourth dose vaccination. Reactogenicity occurrences of grade 3 or higher often displayed a similar trend. Approximately 73% of participants experienced any grade of solicited local reactions such as soreness, discomfort, swelling, or erythema, with Grade 3+ reported by 19% of individuals after receiving the fourth dose.

On the other hand, 83% of participants reported adverse events of any grade, and 14% had Grade 3+ events post-third dose. Erythema was experienced more often following the fourth dose, accounting for 20% of any Grade and 15% of Grade 3+ events, compared to 10% for any Grade and 1% for Grade 3+ following the third dose. After the fourth vaccination, local effects were transient.

After an initial decrease noted after the primary vaccination series, a third NVX-CoV2373 vaccine dose raised anti-recombinant spike (rS) immunoglobulin (Ig)-G titers corresponding to the ancestral strain to four times that observed following the primary series. Compared to the reduction after the primary series, titers decreased more gradually following the third dose, while the anti-rS IgG titers rose following the fourth dose to comparable levels as observed after the third dose. As the number of vaccine doses increased, the immune response to SARS-CoV-2 Omicron BA.1 followed a similar trend, with a gradual narrowing of the difference between the extent of the reaction to the ancestral strain and the Omicron BA.1 strain.

Similar patterns were observed between neutralization titers and anti-rS IgG titers. The third vaccination of NVXCoV2373 boosted SARS-CoV-2 neutralization titers against the ancestral strain to almost 4.7 times more than that noted after primary vaccination. Furthermore, the titers elicited by the fourth dose were comparable to those after the third dose.

Neutralization titers corresponding to different SARS-CoV-2 variants were assessed using antigenic distance mapping, revealing a decrease in antigenic distance and fold difference as the number of NVX-CoV2373 doses increased. The antigenic difference between the Omicron BA.4/5 subvariant and the wild-type strain was 33.5-fold following the primary series of NVX-CoV2373 which reduced to 7.1-fold following the third NVX-CoV2373 vaccine dose. After the fourth vaccination, the antigenic distance reduced further to a 3.5-fold distance.

Overall, the study findings showed that the fourth dose of NVX-CoV2373 improved immunogenicity without eliciting an increase in reactogenicity. After the fourth dosage of NVX-CoV2373, antigenic mapping revealed a more uniform response against SARS-CoV-2 variations, indicating that modifications to the vaccine formulation might not be warranted.

*Important notice

medRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

READ ALSO

Lab-made antibodies may be able to cure people infected with yellow fever

Consumption of dried fruits associated with higher-quality diets

Tags: AntibodiesAssayCoronavirusCoronavirus Disease COVID-19EfficacyErythemaHomologousImmune ResponseOmicronPlaceboProteinRespiratorySARSSARS-CoV-2Severe Acute RespiratorySevere Acute Respiratory SyndromeSpike ProteinSyndromeVaccine

Related Posts

Lab-made antibodies may be able to cure people infected with yellow fever
Health

Lab-made antibodies may be able to cure people infected with yellow fever

March 29, 2023
Consumption of dried fruits associated with higher-quality diets
Health

Consumption of dried fruits associated with higher-quality diets

March 29, 2023
Maternal weight gain in pregnancy linked to children's risk of neurodevelopmental disorders
Health

Maternal weight gain in pregnancy linked to children's risk of neurodevelopmental disorders

March 29, 2023
Next-generation influenza vaccines show greater impact and cost-effectiveness, study suggests
Health

Next-generation influenza vaccines show greater impact and cost-effectiveness, study suggests

March 29, 2023
New evidence: Fibromyalgia could worsen opioid use disorder
Health

New evidence: Fibromyalgia could worsen opioid use disorder

March 28, 2023
What is the effect of prior BCG vaccination on the immunogenicity and efficacy of subsequent COVID-19 vaccination?
Health

What is the effect of prior BCG vaccination on the immunogenicity and efficacy of subsequent COVID-19 vaccination?

March 28, 2023
Next Post
Football World Cup in the live ticker: Morocco against Croatia

Football World Cup in the live ticker: Morocco against Croatia

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

POPULAR NEWS

Roblox Is Unbreakable Trello Is this safe?

Roblox Is Unbreakable Trello Is this safe?

November 4, 2022
Discord Registered Games  Discord Registered Gaming You need to join the Club

Discord Registered Games Discord Registered Gaming You need to join the Club

November 4, 2022
How To Chose the Right Data Analytics Program

How To Chose the Right Data Analytics Program

November 4, 2022
Chandrashekhar Guruji Wiki, Age, Girlfriend, Wife, Family, Biography & More

Chandrashekhar Guruji Wiki, Age, Girlfriend, Wife, Family, Biography & More

November 4, 2022
Heavy explosion on market square in Halle – three injured

Heavy explosion on market square in Halle – three injured

November 4, 2022

EDITOR'S PICK

Your Smartphone Is a Haven for Allergens

Your Smartphone Is a Haven for Allergens

November 10, 2022

California’s ambitious electric vehicle plan – how will it impact the energy market?

October 26, 2022

FDP and Union continue to push for Akw runtime extension

September 6, 2022

Werding is to become the new new economic wise man

May 12, 2022

About

Sepoy.net is a perfect place for people who want daily updates on news related to business, technology, entertainment, health, cryptocurrency etc.

Contact: [email protected]

Major Categories

News

Business

Tech

Economy

 

Recent Posts

  • Lab-made antibodies may be able to cure people infected with yellow fever
  • Degrowth movement: do we have to shrink the economy for the climate?
  • More ways IFRS 17 can make for wonky reporting

Pages

  • About Us
  • Contact Us
  • Disclaimer
  • DMCA
  • Home
  • Privacy Policy

© 2023 Sepoy.net

No Result
View All Result
  • Home
  • Business
  • News
  • Health
  • Tech
  • Science
  • Lifestyle
  • Travel

© 2023 Sepoy.net